Erica L Mayer

Erica L Mayer

UNVERIFIED PROFILE

Are you Erica L Mayer?   Register this Author

Register author
Erica L Mayer

Erica L Mayer

Publications by authors named "Erica L Mayer"

Are you Erica L Mayer?   Register this Author

46Publications

966Reads

5Profile Views

Blocking the Cycle: Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic, Hormone Receptor-Positive Breast Cancer.

J Clin Oncol 2017 Sep 3;35(25):2866-2870. Epub 2017 Jun 3.

Seth A. Wander, Erica L. Mayer, and Harold J. Burstein, Dana-Farber Cancer Institute; Brigham & Women's Hospital; Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.73.9482DOI Listing
September 2017

Prognosis of pregnancy-associated breast cancer.

Breast Cancer Res Treat 2017 Jun 1;163(3):417-421. Epub 2017 Apr 1.

Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-017-4224-6DOI Listing
June 2017

Tamoxifen Directly Inhibits Platelet Angiogenic Potential and Platelet-Mediated Metastasis.

Arterioscler Thromb Vasc Biol 2017 04 2;37(4):664-674. Epub 2017 Feb 2.

From the Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Boston, MA (K.E.J., J.A.F., M.D.T., J.R.C., S.E.-H., R.K., K.R.M., J.E.I., E.M.B.); Department of Medicine, Harvard Medical School, Boston, MA (K.E.J., K.R.M., E.L.M., J.E.I., E.M.B.); Vascular Biology Program, Department of Surgery, Children's Hospital Boston, MA (J.E.I.); and Division of Hematology, Dana-Farber Cancer Institute, Boston, MA (E.L.M.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/ATVBAHA.116.308791DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5364056PMC
April 2017

Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline.

J Clin Oncol 2017 Mar 5;35(8):893-911. Epub 2016 Dec 5.

Saro H. Armenian, City of Hope, Duarte, CA; Christina Lacchetti, American Society of Clinical Oncology, Alexandria; Neelima Denduluri, Virginia Cancer Specialists, Arlington, VA; Ana Barac, Medstar Heart Institute, Medstar Washington Hospital Center, Washington, DC; Joseph Carver and Mariell Jessup, University of Pennsylvania; Bonnie Ky, Hospital of the University of Pennsylvania, Philadelphia, PA; Louis S. Constine, University of Rochester Medical Center, Rochester; Lee W. Jones and Kevin Oeffinger, Memorial Sloan Kettering Cancer Center, New York, NY; Susan Dent, The Ottawa Hospital Cancer Center, Ottawa, Ontario, Canada; Pamela S. Douglas, Duke University, Durham, NC; Jean-Bernard Durand and Michael Ewer, The University of Texas MD Anderson Cancer Center, Houston, TX; Carol Fabian, University of Kansas Medical Center, Kansas City, KS; Melissa Hudson, St Jude Children's Research Hospital, Memphis; Javid Moslehi and Daniel Lenihan, Vanderbilt University; Katharine Ray, Patient Representative, Nashville, TN; Erica L. Mayer, Dana-Farber Cancer Institute, Boston, MA; and Kathryn Ruddy, Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.5400DOI Listing
March 2017

Chemotherapy for Triple-Negative Breast Cancer: Is More Better?

J Clin Oncol 2016 10 22;34(28):3369-71. Epub 2016 Aug 22.

Dana-Farber Cancer Institute, Brigham & Women's Hospital, and Harvard Medical School, Boston, MA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.4068DOI Listing
October 2016

Evaluating the Utility of Baseline Cardiac Function Screening in Early-Stage Breast Cancer Treatment.

Oncologist 2016 06 22;21(6):666-70. Epub 2016 Apr 22.

Harvard Medical School, Boston, Massachusetts, USA Dana-Farber Cancer Institute, Boston, Massachusetts, USA Brigham and Women's Hospital, Boston, Massachusetts, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2015-0449DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4912366PMC
June 2016

Targeting breast cancer with CDK inhibitors.

Authors:
Erica L Mayer

Curr Oncol Rep 2015 ;17(5):443

Susan F Smith Center for Women's Cancers, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02215, USA,

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/s11912-015-0443
Web Search
http://link.springer.com/10.1007/s11912-015-0443-3
Publisher Site
http://dx.doi.org/10.1007/s11912-015-0443-3DOI Listing
December 2015

Early and late long-term effects of adjuvant chemotherapy.

Authors:
Erica L Mayer

Am Soc Clin Oncol Educ Book 2013 :9-14

From the Breast Oncology Center, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EdBook_AM.2013.33.9DOI Listing
November 2015

Adjuvant endocrine therapy for postmenopausal women: Type and duration.

Breast 2015 Nov 14;24 Suppl 2:S126-8. Epub 2015 Aug 14.

Dana-Farber Cancer Institute, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://www.jhasim.com/files/articlefiles/pdf/ASM_6_10C_p984_
Web Search
http://linkinghub.elsevier.com/retrieve/pii/S096097761500166
Publisher Site
http://dx.doi.org/10.1016/j.breast.2015.07.028DOI Listing
November 2015

Postmenopausal breast cancer: a best endocrine strategy?

Lancet 2015 Oct 23;386(10001):1317-1319. Epub 2015 Jul 23.

Susan F Smith Center for Women's Cancers, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(15)61206-5DOI Listing
October 2015

Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance).

J Clin Oncol 2015 Jul 8;33(21):2361-9. Epub 2015 Jun 8.

Hope S. Rugo, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; William T. Barry, Alliance Statistics and Data Center, Dana-Farber Cancer Institute; Erica L. Mayer and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Alvaro Moreno-Aspitia and Edith A. Perez, Mayo Clinic, Jacksonville, FL; Alan P. Lyss, Heartland Cancer Research Community Clinical Oncology Program; Michael Naughton, Washington University School of Medicine, St Louis, MO; Constance Cirrincione and Eleanor Leung, Alliance Statistics and Data Center, Duke University, Durham; Lisa A. Carey, University of North Carolina, Chapel Hill, NC; Deborah Toppmeyer, Cancer Institute of New Jersey, New Brunswick, NJ; and Clifford Hudis, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.59.5298DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4500830PMC
July 2015

TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.

J Clin Oncol 2015 Jun 6;33(17):1902-9. Epub 2015 Apr 6.

Steven J. Isakoff, Lei He, Darrel R. Borger, Dianne M. Finkelstein, Paula D. Ryan, Paul E. Goss, and Leif W. Ellisen, Massachusetts General Hospital Cancer Center; Steven J. Isakoff, Erica L. Mayer, Lei He, Karen Krag, Steven E. Come, Darrel R. Borger, Dianne M. Finkelstein, Judy E. Garber, Paula D. Ryan, Eric P. Winer, Paul E. Goss, and Leif W. Ellisen, Harvard Medical School; Erica L. Mayer, Judy E. Garber, and Eric P. Winer, Dana-Farber Cancer Institute; Steven E. Come, Beth Israel Deaconess Medical Center, Boston; Karen Krag, Massachusetts General Hospital/North Shore Cancer Center, Danvers, MA; Tiffany A. Traina, Memorial Sloan Kettering Cancer Center, New York, NY; Lisa A. Carey, The University of North Carolina at Chapel Hill, Chapel Hill, NC; Hope S. Rugo, University of California at San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Minetta C. Liu, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Vered Stearns, The Johns Hopkins University School of Medicine and The Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Kirsten Timms, Myriad Genetics; and Anne-Renee Hartman, Myriad Genetic Laboratories, Salt Lake City, UT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.57.6660DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451173PMC
June 2015

Breast cancer axillary staging: much ado about micrometastatic disease.

J Clin Oncol 2015 Apr 23;33(10):1095-7. Epub 2015 Feb 23.

Dana-Farber/Brigham and Women's Cancer Center, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.59.2303DOI Listing
April 2015

Inhibition of cyclin-dependent kinases 4 and 6 in breast cancer.

Authors:
Erica L Mayer

Clin Adv Hematol Oncol 2015 Apr;13(4):215-7

Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
April 2015

Circulating tumor cell analysis in metastatic triple-negative breast cancers.

Clin Cancer Res 2015 Mar 18;21(5):1098-105. Epub 2014 Dec 18.

University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-1948DOI Listing
March 2015

Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice.

Breast Cancer Res Treat 2013 Oct 24;141(3):421-7. Epub 2013 Sep 24.

Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-013-2700-1DOI Listing
October 2013

A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer.

Breast Cancer Res Treat 2013 Jul 19;140(2):331-9. Epub 2013 Jul 19.

Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-013-2632-9DOI Listing
July 2013

Reply to V. Pitini et al.

J Clin Oncol 2013 Jun;31(17):2225-6

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.48.3719DOI Listing
June 2013

Breast cancer survivors' perceptions of survivorship care options.

J Clin Oncol 2012 Jan 12;30(2):158-63. Epub 2011 Dec 12.

Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2011.36.9264DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4874208PMC
January 2012

Congestive heart failure risk in patients with breast cancer treated with bevacizumab.

J Clin Oncol 2011 Feb 4;29(6):632-8. Epub 2011 Jan 4.

Dana-Farber Cancer Institute, 44 Binney St (Dana 1230), Boston MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2010.31.9129DOI Listing
February 2011

Cardiac toxicity from systemic cancer therapy: a comprehensive review.

Prog Cardiovasc Dis 2010 Sep-Oct;53(2):94-104

Division of Medical Oncology, Department of Medicine, Istituto Europeo di Oncologia, Miano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pcad.2010.05.006DOI Listing
September 2010

Advances in targeting SRC in the treatment of breast cancer and other solid malignancies.

Clin Cancer Res 2010 Jul;16(14):3526-32

Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-09-1834DOI Listing
July 2010

Chemotherapy for metastatic breast cancer.

Hematol Oncol Clin North Am 2007 Apr;21(2):257-72

Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2007.03.001DOI Listing
April 2007

Novel approaches to advanced breast cancer: bevacizumab and lapatinib.

J Natl Compr Canc Netw 2007 Mar;5(3):314-23

Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
March 2007